Lenabasum is a Small Molecule owned by Corbus Pharmaceuticals, and is involved in 8 clinical trials, which were completed.

Lenabasum is a synthetic cannabinoid CB2 agonist. When Resunab binds to CB2 receptors on immune cells it shifts the arachidonic acid metabolic pathways leading to the production of spectrum of anti-inflammatory mediators such as PGJ2 and Lipoxin A4 that are part of the naturally off-switch for inflammation. JBT-101 reduces immune mediated inflammation and tissue injury by acting on and influencing cellular immunity, inhibiting leukocyte migration, reducing cytokines secretion (IL-1, IL-6 and IL-8), inhibiting matrix metalloproteinase production (MMP-1, -3, -9), reducing pro-inflammatory eicosanoid levels (PGE2, LTB4) and increasing resolving eicosanoid production (PGJ2, LXA4).

The revenue for Lenabasum is expected to reach a total of $230m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Lenabasum NPV Report.

Lenabasum was originated by UMass Chan Medical School and is currently owned by Corbus Pharmaceuticals. Corbus Pharmaceuticals Holdings is the other company associated in development or marketing of Lenabasum.

Lenabasum Overview

Lenabasum is under development for the treatment of systemic lupus erythematosus, diffuse cutaneous systemic sclerosis. It is an oral endo cannabinoid mimetic. The drug candidate acts by targeting cannabinoid receptor 2 (CB2). JBT-101 a nanomolar cannabinoid and is based on the core structure of Tetrahydrocannabinol (THC). It was under development for the treatment of bladder pain, inflammatory disorders and bladder overactivity in hypersensitive bladder disorders such as interstitial cystitis, cystic fibrosis, skin-predominant dermatomyositis and neuropathic pain. It is a new chemical entity (NCE). 

Corbus Pharmaceuticals Holdings Overview

Corbus Pharmaceuticals Holdings (Corbus Pharmaceuticals) is a clinical-stage pharmaceutical company that develops and commercializes novel therapeutics to treat inflammatory and fibrotic diseases. The company’s pipeline product portfolio includes Lenabasum, an oral small-molecule for the treatment of inflammatory diseases; CRB-4001, to treat fibrotic diseases. It serves in the therapeutic areas of chronic inflammation, autoimmune diseases, allergies and orphan diseases. Corbus Pharmaceuticals collaborates with National Institutes of Health (NIH) for in the development of drugs. The company has operations in Europe, Israel, and Australia. Corbus Pharmaceuticals is headquartered in Norwood, Massachusetts, the US.

The company reported revenues of (US Dollars) US$0.9 million for the fiscal year ended December 2021 (FY2021), a decrease of 77.6% over FY2020. The operating loss of the company was US$56 million in FY2021, compared to an operating loss of US$122.8 million in FY2020. The net loss of the company was US$45.6 million in FY2021, compared to a net loss of US$111.3 million in FY2020.

Quick View – Lenabasum

Report Segments
  • Innovator
Drug Name
  • Lenabasum
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Immunology
  • Musculoskeletal Disorders
  • Respiratory
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.